换一批
换一批Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
第一作者：
Nozomi,Niitsu
第一单位：
Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan. nniitsu@med.kitasato-u.ac.jp
作者：
主题词
成年人(Adult);抗体, 单克隆(Antibodies, Monoclonal);抗体, 单克隆, 鼠源性(Antibodies, Monoclonal, Murine-Derived);抗体依赖细胞细胞毒性(Antibody-Dependent Cell Cytotoxicity);抗原(Antigens);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);细胞膜(Cell Membrane);环磷酰胺(Cyclophosphamide);多柔比星(Doxorubicin);女(雌)性(Female);粒细胞集落刺激因子(Granulocyte Colony-Stimulating Factor);粒细胞巨噬细胞集落刺激因子(Granulocyte-Macrophage Colony-Stimulating Factor);人类(Humans);免疫表型分型(Immunophenotyping);白细胞介素10(Interleukin-10);白细胞介素4(Interleukin-4);淋巴瘤, 滤泡性(Lymphoma, Follicular);男(雄)性(Male);中年人(Middle Aged);中性白细胞(Neutrophils);泼尼松龙(Prednisolone);受体, IgG(Receptors, IgG);时间因素(Time Factors);治疗结果(Treatment Outcome);长春新碱(Vincristine)
DOI
10.1158/1078-0432.CCR-03-0658
PMID
15217942
发布时间
2015-11-19
- 浏览24
Clinical cancer research
4077-82页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
